Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Stock Information for Precision BioSciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Precision BioSciences Inc.

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025
Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases
Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.